Enlivex (ENLV) FCF Margin (2022 - 2025)
Enlivex (ENLV) posted quarterly FCF Margin of 120.27% for Q1 2025, up 2429.0% year-over-year from 4.76% in Q1 2024, and up 415.85% quarter-over-quarter from 38.08% in Q4 2024.
Enlivex (ENLV) FCF Margin (2022 - 2025) Analysis & Trends
Enlivex's FCF Margin history runs 4 years deep, the most recent figure standing at 120.27% for Q1 2025.
- In Q1 2025, FCF Margin rose 2429.0% year-over-year to 120.27%; the TTM figure through Mar 2025 stood at 53.81% (up 164446.0% YoY), while the FY2024 annual figure was 35.49%, down 4508.0% from the prior year.
- FCF Margin for Q1 2025 stood at 120.27%, up from 38.08% in the prior quarter.
- The five-year high for FCF Margin was 120.27% in Q1 2025, with the low at 38.08% in Q4 2024.
- The 4-year median for FCF Margin is 50.67% (2022), against an average of 42.22%.
- The sharpest annual moves came in 2023 and 2024: FCF Margin jumped 4506 bps in 2023, then sank 1186 bps in 2024.
- Enlivex's FCF Margin stood at 28.15% in 2022, then slumped by 193 bps to 26.22% in 2023, then plunged by 45 bps to 38.08% in 2024, then surged by 416 bps to 120.27% in 2025.
- Business Quant data shows ENLV's FCF Margin at 120.27% in Q1 2025, 38.08% in Q4 2024, and 95.98% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 70.82% |
| 10 | Enlivex | 4.42 Mn | -1.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 120.27% |
| Dec 31, 2024 | -38.08% |
| Mar 31, 2024 | 95.98% |
| Dec 31, 2023 | -26.22% |
| Mar 31, 2023 | 73.20% |
| Mar 31, 2022 | 28.15% |